| 37 | 0 | 43 |
| 下载次数 | 被引频次 | 阅读次数 |
RNA编辑是转录后修饰的重要过程。A-to-I RNA编辑是RNA编辑最主要和常见的一种，它由RNA腺苷脱氨酶（ADAR）催化。其中，ADAR1是ADAR家族最重要的亚型。近年来，ADAR1在多种生物学过程中的作用受到了广泛关注，尤其是在先天免疫方面。炎症是先天免疫的重要一环。ADAR1通过编辑免疫相关基因，影响dsRNA（双链RNA）免疫感受器识别，调控炎症信号通路的激活，从而参与调节炎症反应。ADAR1的表达和活性受到多种信号通路的调控，这些信号通路在炎症过程中起着关键作用。此外，在多种疾病中ADAR1的活性表现出异常，包括急性炎症性疾病、自身免疫性疾病以及病毒感染等。该综述基于最新研究形成的整体认识，旨在归纳ADAR1对炎症反应的调控机制，总结ADAR1活性异常导致疾病的最新研究进展。
Abstract：RNA editing is a crucial process in post-transcriptional modification. Among various types of RNA editing， A-to-I (adenosine-to-inosine) RNA editing is the most predominant and common one， which is catalyzed by adenosine deaminases acting on RNA (ADARs). Notably， ADAR1 is the most important isoform in the ADAR family. In recent years， the role of ADAR1 in multiple biological processes has attracted extensive attention， particularly in the field of innate immunity. Inflammation is a key component of innate immunity. ADAR1 participates in the regulation of inflammatory responses by editing immunity-related genes， affecting the recognition of double-stranded RNA (dsRNA) by immune sensors， and modulating the activation of inflammatory signaling pathways. The expression and activity of ADAR1 are regulated by a variety of signaling pathways， which play critical roles in the inflammatory process. Furthermore， abnormal ADAR1 activity has been observed in a range of diseases， including acute inflammatory diseases， autoimmune diseases， and viral infections. This review aims to summarize the regulatory mechanisms of ADAR1 in inflammatory responses and the research progress on diseases caused by abnormal ADAR1 activity. This review， based on the overall understanding formed from the latest research， aims to summarize the regulatory mechanism of ADAR1 on inflammatory responses and to review the latest research progress on diseases caused by abnormal ADAR1 activity.
[1] Ma M， Jiang W， Zhou R. DAMPs and DAMP-sensing receptors in inflammation and diseases[J]. Immunity， 2024， 57(4): 752-71. doi:10.1016/j.immuni.2024.03.002.
[2] Cottrell K A， Andrews R J， Bass B L. The competitive landscape of the dsRNA world[J]. Mol Cell， 2024， 84(1): 107-19. doi:10.1016/j.molcel.2023.11.033.
[3] Nishikura K. A-to-I editing of coding and non-coding RNAs by ADARs[J]. Nat Rev Mol Cell Biol， 2016， 17(2): 83-96. doi:10.1038/nrm.2015.4.
[4] Baker A R， Slack F J. ADAR1 and its implications in cancer development and treatment[J]. Trends Genet， 2022， 38(8): 821-30. doi:10.1016/j.tig.2022.03.013.
[5] Rehwinkel J， Mehdipour P. ADAR1: from basic mechanisms to inhibitors[J]. Trends Cell Biol， 2025， 35(1): 59-73. doi:10.1016/j.tcb.2024.06.006.
[6] Cai Z Y， Wu P， Liang H， et al. A ZBP1 isoform blocks ZBP1-mediated cell death[J]. Cell Rep， 2024， 43(5): 114221. doi:10.1016/j.celrep.2024.114221.
[7] Mishra S， Dey A A， Kesavardhana S. Z-nucleic acid sensing and activation of ZBP1 in cellular physiology and disease pathogenesis[J]. Immunol Rev， 2025， 329(1): e13437. doi:10.1111/imr.13437.
[8] de Reuver R， Verdonck S， Dierick E， et al. ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation[J]. Nature， 2022， 607(7920): 784-9. doi:10.1038/s41586-022-04974-w.
[9] Hubbard N W， Ames J M， Maurano M， et al. ADAR1 mutation causes ZBP1-dependent immunopathology[J]. Nature， 2022， 607(7920): 769-75. doi:10.1038/s41586-022-04896-7.
[10] Karki R， Sundaram B， Sharma B R， et al. ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis[J]. Cell Rep， 2021， 37(3): 109858. doi:10.1016/j.celrep.2021.109858.
[11] Hu S B， Heraud-Farlow J， Sun T， et al. ADAR1p150 prevents MDA5 and PKR activation via distinct mechanisms to avert fatal autoinflammation[J]. Mol Cell， 2023， 83(21): 3869-84.e7. doi:10.1016/j.molcel.2023.09.018.
[12] Hartner J C， Walkley C R， Lu J， et al. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling[J]. Nat Immunol， 2009， 10(1): 109-15. doi:10.1038/ni.1680.
[13] Pestal K， Funk C C， Snyder J M， et al. Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development[J]. Immunity， 2015， 43(5): 933-44. doi:10.1016/j.immuni.2015.11.001.
[14] Hoang H D， Graber T E， Alain T. Battling for ribosomes: translational control at the forefront of the antiviral response[J]. J Mol Biol， 2018， 430(14): 1965-92. doi:10.1016/j.jmb.2018.04.040.
[15] Schulz O， Pichlmair A， Rehwinkel J， et al. Protein kinase R contributes to immunity against specific viruses by regulating interferon mRNA integrity[J]. Cell Host Microbe， 2010， 7(5): 354-61. doi:10.1016/j.chom.2010.04.007.
[16] Wang Q， Miyakoda M， Yang W， et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene[J]. J Biol Chem， 2004， 279(6): 4952-61. doi:10.1074/jbc.M310162200.
[17] Sinigaglia K， Cherian A， Du Q， et al. An ADAR1 dsRBD3-PKR kinase domain interaction on dsRNA inhibits PKR activation[J]. Cell Rep， 2024， 43(8): 114618. doi:10.1016/j.celrep.2024.114618.
[18] Drappier M， Jha B K， Stone S， et al. A novel mechanism of RNase L inhibition: theiler’s virus L* protein prevents 2-5A from binding to RNase L[J]. PLoS Pathog， 2018， 14(4): e1006989. doi:10.1371/journal.ppat.1006989.
[19] Chen W， Li Y， Ruan G X， et al. Adenosine deaminase acting on RNA-1 is essential for early B lymphopoiesis[J]. Cell Rep， 2022， 41(8): 111687. doi:10.1016/j.celrep.2022.111687.
[20] Li Y， Banerjee S， Goldstein S A， et al. Ribonuclease L mediates the cell-lethal phenotype of double-stranded RNA editing enzyme ADAR1 deficiency in a human cell line[J]. eLife， 2017， 6: e25687. doi:10.7554/eLife.25687.
[21] Rice G I， Kasher P R， Forte G M， et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature[J]. Nat Genet， 2012， 44(11): 1243-8. doi:10.1038/ng.2414.
[22] Yang J H， Luo X， Nie Y， et al. Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response to inflammation[J]. Immunology， 2003， 109(1): 15-23. doi:10.1046/j.1365-2567.2003.01598.x.
[23] Wu Y， Wang H， Zhang J， et al. Adenosine deaminase that acts on RNA 1 p150 in alveolar macrophage is involved in lps-induced lung injury[J]. Shock， 2009， 31(4): 410-5. doi:10.1097/shk.0b013e31817c1068.
[24] Xu L， Zhang L， Wei W. Research progress of inflammasomes in autoimmune diseases[J]. J Anhui Med Univ， 2020， 55(9): 1479-82. doi:10.19405/j.cnki.issn1000-1492.2020.09.033.
[25] Liu S， Xie J， Zhao B， et al. Corrigendum to “ADAR1 prevents small intestinal injury from inflammation in a murine model of sepsis” [Cytokine 104 (2018) 30–37[J]. Cytokine， 2023， 167: 156225. doi:10.1016/j.cyto.2023.156225.
[26]Crow Y J， Manel N. Aicardi–Goutières syndrome and the type I interferonopathies[J]. Nat Rev Immunol， 2015， 15(7): 429-40. doi:10.1038/nri3850.
[27] Guo X， Wiley C A， Steinman R A， et al. Aicardi-Goutières syndrome-associated mutation at ADAR1 gene locus activates innate immune response in mouse brain[J]. J Neuroinflammation， 2021， 18(1): 169. doi:10.1186/s12974-021-02217-9.
[28] Roth S H， Danan-Gotthold M， Ben-Izhak M， et al. Increased RNA editing may provide a source for autoantigens in systemic lupus erythematosus[J]. Cell Rep， 2018， 23(1): 50-7. doi:10.1016/j.celrep.2018.03.036.
[29] Vogel O A， Han J， Liang C Y， et al. The p150 isoform of ADAR1 blocks sustained RLR signaling and apoptosis during influenza virus infection[J]. PLoS Pathog， 2020， 16(9): e1008842. doi:10.1371/journal.ppat.1008842.
[30] Koehler H， Cotsmire S， Zhang T， et al. Vaccinia virus E3 prevents sensing of Z-RNA to block ZBP1-dependent necroptosis[J]. Cell Host Microbe， 2021， 29(8): 1266-76.e5. doi:10.1016/j.chom.2021.05.009.
基本信息:
中图分类号:R364.5
引用信息:
[1]李雨森,顾林贵,李书鹏,等.ADAR1在炎症中的研究进展[J].安徽医科大学学报().
基金信息:
国家自然科学基金面上项目(编号：32270799)
2026-09-11
2026-09-11
2026-09-11